SHPMY (Shanghai Pharmaceuticals Holding Co) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHPMY Shanghai Pharmaceuticals Holding Co Ltd SHPMY
79 GF Score
Price $7.34
GF Value $8.83
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Pharmaceuticals Holding Co SpecialCharges?

Special Charges only applies to banks.

SHPMY
79GF Score
Shanghai Pharmaceuticals Holding Co Ltd SHPMY
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shanghai Pharmaceuticals Holding Co (SHPMY) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued. The current stock price of $7.34 is trading 16.9% below its estimated GF Value™ of $8.83. GuruFocus considers Shanghai Pharmaceuticals Holding Co to be Modestly Undervalued.

Key valuation signals for SHPMY:

  • SpecialCharges:
  • GF Value™: $8.83 vs. price of $7.34 (16.9% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the SHPMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Pharmaceuticals Holding Co Business Description

Address No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
79GF Score

Get the complete analysis for SHPMY

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.34
Price
$8.83
GF Value